Skip to main content

Table 2 Summary of risk factors for CBC and levels of evidence [8]

From: The Manchester guidelines for contralateral risk-reducing mastectomy

Family history—<45 years with a first-degree relative (RR 2.5)

—<55 years with first degree relative (RR 1.5)

—first degree relative with bilateral disease (RR 3.5)

Level II evidence (Reiner AS JCO—2013) [18]

Gene mutation status—BRCA1/2 mutation (RR4)

Level II evidence (Metcalfe 2004 JCO; Evans 2013) [4, 25]

Chest radiotherapy for Hodgkin’s lymphoma—rate of CBC unknown

Young age at diagnosis—<30 years 0.5–1.3 % annual CBC rate

Level II evidence (Nichols, Lacey JCO 2011) [2]

ER status—ER positive (reference point RR 1)

—ER negative (RR 1.3)

Level II evidence [26]

Anti-endocrine treatment (risk reduction), tamoxifen 50 %

Aromatase inhibitor 70 %

Level I evidence [27, 28]

DCIS—0.6 % annual CBC risk of DCIS and/or invasive carcinoma

(RR 1.0)

Level I evidence [21]

Lobular histology combined with family history (RR2.0)

Oophorectomy under 40 years (risk reduction) (RR0.5)

Early menopause <45 year (risk-reduction)—published as abstract [29]